tetano
Editor, Senior Moderator
Diseases
. 2021 Aug 27;9(3):58.
doi: 10.3390/diseases9030058.
Skin Adverse Reactions to Novel Messenger RNA Coronavirus Vaccination: A Case Series
Maria Francesca Peigottu[SUP] 1 [/SUP], Caterina Ferreli[SUP] 2 [/SUP], Maria Giovanna Atzori[SUP] 1 [/SUP], Laura Atzori[SUP] 2 [/SUP]
Affiliations
Abstract
Vaccines are actually the most effective strategy to control the COVID-19 spread and reduce mortality, but adverse reactions can occur. Skin involvement with novel messenger RNA coronavirus vaccines seems frequent but is not completely characterized. A real-world experience in the recent vaccination campaign among health care workers in Sardinia (Italy) is reported. In over a total of 1577 persons vaccinated, 9 cases of skin adverse reactions were observed (0.5%). All reactions have been reported to the Italian Pharmacovigilance Authority. Eight occurred in women (mean age 46 years), and five were physicians and four nurses. All patients had a significant allergology history but not for the known vaccine excipients. After dose one, no injection site reactions were observed, but widespread pruritus (n = 3), mild facial erythema (n = 1), and maculopapular rash (n = 3) occurred in the following 24-48 h in three patients. These three patients were excluded from the second dose. Of the remaining six patients, one developed mild anaphylaxis within the observation period at the vaccination hub and five delayed facial erythematous edema and maculopapular lesions, requiring antihistamines and short-course corticosteroid treatment. Spontaneous reporting is paramount to adjourning vaccination guidance and preventive measures in order to contribute to the development of a safe vaccine strategy. Dermatologist' expertise might provide better characterization, treatment, and screening of individuals at high risk of skin adverse reactions.
Keywords: COVID-19 vaccination; delayed skin reactions; novel messenger RNA coronavirus vaccine; skin adverse reactions.
. 2021 Aug 27;9(3):58.
doi: 10.3390/diseases9030058.
Skin Adverse Reactions to Novel Messenger RNA Coronavirus Vaccination: A Case Series
Maria Francesca Peigottu[SUP] 1 [/SUP], Caterina Ferreli[SUP] 2 [/SUP], Maria Giovanna Atzori[SUP] 1 [/SUP], Laura Atzori[SUP] 2 [/SUP]
Affiliations
- PMID: 34562965
- DOI: 10.3390/diseases9030058
Abstract
Vaccines are actually the most effective strategy to control the COVID-19 spread and reduce mortality, but adverse reactions can occur. Skin involvement with novel messenger RNA coronavirus vaccines seems frequent but is not completely characterized. A real-world experience in the recent vaccination campaign among health care workers in Sardinia (Italy) is reported. In over a total of 1577 persons vaccinated, 9 cases of skin adverse reactions were observed (0.5%). All reactions have been reported to the Italian Pharmacovigilance Authority. Eight occurred in women (mean age 46 years), and five were physicians and four nurses. All patients had a significant allergology history but not for the known vaccine excipients. After dose one, no injection site reactions were observed, but widespread pruritus (n = 3), mild facial erythema (n = 1), and maculopapular rash (n = 3) occurred in the following 24-48 h in three patients. These three patients were excluded from the second dose. Of the remaining six patients, one developed mild anaphylaxis within the observation period at the vaccination hub and five delayed facial erythematous edema and maculopapular lesions, requiring antihistamines and short-course corticosteroid treatment. Spontaneous reporting is paramount to adjourning vaccination guidance and preventive measures in order to contribute to the development of a safe vaccine strategy. Dermatologist' expertise might provide better characterization, treatment, and screening of individuals at high risk of skin adverse reactions.
Keywords: COVID-19 vaccination; delayed skin reactions; novel messenger RNA coronavirus vaccine; skin adverse reactions.